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Abstract
Human IgG1 antibody responses are associated with protection against Schistosoma haematobium infection and are now a
target for schistosome vaccine development. This study aimed to investigate the relationship between total IgG and the IgG
subclasses and the monocyte IgG receptor, known as FccRIIIa or CD16, in schistosome exposed people. Systemic levels of
schistosome-specific anti-adult worm total IgG and IgG subclass titres were measured by ELISA in 100 individuals from an S.
haematobium endemic area in Zimbabwe and, using parametric statistical methods and regression analysis, related to the
levels of CD16 expression on individuals’ circulating monocytes, determined via flow cytometry. Monocyte CD16 expression
rose with parasite-specific total IgG and IgG1 in healthy participants, but not in schistosome infected patients. Similar to
parasite-specific IgG and IgG1, CD16 expression in healthy individuals is associated with protection against schistosome
infection. This relationship indicates a mechanistic link between the innate and adaptive immune responses to helminth
infection in protection against infection. Further understanding the elements of a protective immune response in
schistosomiasis may aid in efforts to develop a protective vaccine against this disease.
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Introduction
An estimated 200 million people worldwide are infected with
helminths of the genus Schistosoma, with the heaviest burden of
disease occurring in sub-Saharan Africa, where both Schistosoma
haematobium and Schistosoma mansoni are endemic, causing
significant morbidity amongst affected communities [1]. Infection
and disease are controlled by treatment with the drug praziquantel
(PZQ), and the World Health Organization (WHO) recommends
protective chemotherapy via mass drug administration (MDA)
with PZQ in endemic areas [2]. There is mounting pressure to
develop a vaccine against schistosomiasis, which would provide
long term protection to the 650 million people at risk of exposure
[3], and pre-empt the development of drug resistance. Current
vaccine development research focuses on determining which
naturally developed immune responses are associated with
protective immunity that develops in the context of endemic
exposure to infection, and investigate ways of inducing those
responses artificially whilst avoiding a pathological response [4,5].
While significant progress has been made in characterising
humoral and cellular responses in experimental models, relatively
less work has been conducted relating the innate and adaptive
arms of the immune system in schistosome infected versus
uninfected humans. In particular, there is a paucity of studies
simultaneously determining cellular and related humoral responses
associated with natural protection against schistosome infection.
Experimental studies have shown links between innate cells
from the myeloid lineage and resistance to helminth infection. For
example, murine macrophages and are involved with tissue repair
and fibrosis [6,7], as well as in limiting pathology by regulating
Type 2 cytokine production [8,9] and inhibiting T cell prolifer-
ation [10]. This current study focused on circulating monocytes,
myeloid cells related developmentally to macrophages, which are
present in the blood vessels and are thus easily accessible for
investigation in humans. Studies from several decades ago showed
a direct role ex vivo for human PBMC-derived monocytes in the
killing of schistosomula [11–13]. Similar to macrophages, mono-
cytes display phagocytic capabilities and express varying levels of
the FccRIIIa (also known as the CD16 receptor) [14], which is
related to distinctions in their phenotype and function in a range of
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pro-inflammatory conditions [15,16]. The Fcc receptors have a
critical role in immune regulation, acting as a link between the
humoral and innate cellular arms of the immune response [17]. In
humans, the CD16 receptor exhibits high affinity binding to the Fc
portion of IgG antibodies, with high affinity binding demonstrated
to IgG1 and IgG3, which leads to phagocytosis, release of
inflammatory mediators and clearance of immune complexes [14].
The importance of the interaction between IgG and Fcc receptors
has been demonstrated in experimental models, whereby there is a
diminished macrophage effector function induced after IgG1-
mediated phagocytosis in Fcc chain knock-out mice [18].
Furthermore, S. mansoni infection exacerbated granuloma
formation and fibrosis in both Fcc receptor and in B cell deficient
mice [19], highlighting the importance of antibody signalling via
the Fcc receptor in protection against pathology associated with
schistosomiasis infection. However, there are few studies relating
IgG subclasses to the Fcc receptors in human schistosomiasis. To
address this knowledge gap, the present study focuses on the
relationship between CD16 and the IgG subclasses.
Our previous studies, and those of others, have shown that, in
humans, schistosome-specific IgG1 and IgG3 antibodies are
associated with natural resistance to infection [20–22]. Induction
of helminth-specific IgG1 and IgG3 through vaccination is now
preferred over IgE to avoid generating IgE-mediated pathological
responses to vaccination [4,23] and, in particular, this study
focuses on these protective subclasses.
This study, therefore, investigated the relationship between
levels of the IgG receptor, FccRIIIa (CD16) and schistosome
specific IgG subclasses in uninfected, healthy individuals versus
schistosome infected patients. The healthy individuals comprised
of young people, who had yet to acquire schistosome infection,
and older people who were putatively resistant to infection, as they
were infection free despite being lifelong residents of the
schistosome endemic areas and experiencing regular exposure to
infective water. The study focused on adult schistosome-specific
IgG responses since adult worms reside in the circulating blood,
and thus are in direct contact with monocytes in this compart-
ment. In addition, our studies, as well as those of others, have
highlighted the importance of the adult worm stage in stimulating
protective immune responses [24–27].
Methods
Ethical approval
Ethical and institutional approval was granted by the Medical
Research Council of Zimbabwe and the University of Zimbabwe’s
Institutional Review Board. Local permission for the study was
granted by the Provincial Medical Director. The study design,
aims and procedures were explained in the local language, Shona,
prior to enrolment. Participants were free to drop out of the study
at any time and informed written consent/assent was obtained
from all participants and/or their guardians prior to taking part in
the study and to receiving antihelminthic treatment.
Study design
The study presented here was part of a larger on-going
immuno-epidemiological study based in Mashonaland East,
Zimbabwe where S. haematobium is endemic [28]. The area has
a low prevalence of soil transmitted helminths (STH) and
Schistosoma mansoni [29], and the residents are subsistence
farmers with frequent contact with infected water for purposes
of bathing, washing and collecting water. Recruitment into the
study was school based and the wider community was also invited
to participate. Residential history, antihelminthic treatment
history and water contact habits of the participants were captured
through questionnaire. Following sample collection, participants
were offered treatment with the antihelminthic drug praziquantel
at the recommended dose of 40 mg/kg of body weight [3].
Inclusion criteria
In order to be included in this study participants had to meet the
following criteria: 1) be lifelong residents of the study area to allow
age to be used as a proxy for history of exposure to schistosome
infection, 2) have provided a minimum of two urine and two stool
samples on consecutive days for parasite detection, 3) not have
previously received antihelminthic treatment, 4) be negative for
co-infection with malaria, STH, S. mansoni and HIV and 5) have
provided a blood sample for serological and cellular assays.
Further to this, participant’s PBMC sample must have yielded at
least 106 cells to allow enough cells for all experimental conditions.
From an initial cohort of 633 recruited individuals, 68 were
excluded for not meeting criteria 1–4 above and a further 184 did
not provide sufficient blood sample for both serological assays and
cell phenotyping. From the remaining 381 individuals, a cohort of
100 individuals was further selected to allow for, as far as possible,
equal numbers of females to males and an even distribution of ages
and infection prevalence. Individuals with one or more S.
haematobium eggs found in their urine samples were classified as
infected. The final study group was divided into three age groups
and is described in Table 1.
Sample collection
From each participant a stool and urine sample was collected on
three consecutive days and examined microscopically for the
presence of S. haematobium eggs in urine, and S. mansoni and
STH eggs in stool using standard techniques [30,31]. A random
sample of 100 stool samples was also processed via the formol
ether concentration technique, and these confirmed Kato Katz
diagnosis [32]. Up to 20 millilitres of venous blood was collected
from each participant in heparinised tubes or silicone –coated
Author Summary
Schistosomiasis is a parasitic disease caused by the
parasite Schistosoma spp. Over 240 million people are
infected worldwide, mainly in Sub-Saharan Africa, but an
efficacious, protective vaccine has yet to be found.
Protection against schistosome infection in individuals
living in endemic areas is mediated by antibodies. In
particular, IgG1 antibody has been shown to be protective
against infection in individuals living in endemic areas, and
eliciting IgG1 production has become a cornerstone of
vaccine development efforts. However, little is known
about the mechanisms by which IgG1 induces protection.
The cell surface molecule CD16 is an IgG antibody receptor
expressed on monocytes and binds preferentially to IgG
antibody subclasses. The work presented here thus
investigates the relationship between IgG levels and the
monocyte CD16 receptor in a population endemically
exposed to infection with schistosomes. We present results
linking CD16 expression with IgG1 levels, whereby
uninfected individuals have a positive relationship be-
tween IgG1 and CD16 expression levels, while schistosome
infected individuals did not show any statistically signifi-
cant relationship between the two. Thus we provide
evidence to suggest a mechanistic link between the innate
and adaptive immune response in parasitic infection,
associating monocyte CD16 expression with a protective
immune response.
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tubes (both from BD Biosciences, San Jose, CA), for purposes of
processing for PBMC purification (heparin tubes), or serum
(silicone tubes) using routine methods. An additional drop of blood
was collected from each participant for microscopic detection of
malaria parasites and for HIV detection using DoubleCheckGold
HIV 1&2 Whole Blood Test (Orgenics Ltd., Yavne, Israel).
Peripheral blood mononuclear cells (PBMC) were isolated from
the remaining tubes via density gradient centrifugation using
Lymphoprep (Axis-Shield, Cambridgeshire, UK). Isolated PBMCs
were cryopreserved and stored in liquid nitrogen in Zimbabwe
prior to freighting to Edinburgh in dry shippers where the overall
viability of isolated PBMCs was estimated in a sample of 84
individuals’ PBMCs using propidium iodide (PI) (Sigma-Aldrich,
Dorset, UK) exclusion. Mean PI uptake in this sample was 15.3%
(+/21.06%), which is within the range considered viable.
Antibody assays
Schistosome soluble worm antigen preparation (SWAP)-specific
antibody serum levels for total IgG, IgG1, IgG2, IgG3 and IgG4
were quantified using antibody ELISA. Lyophilized SWAP
(Theodor Bilharz Institute, Giza, Egypt) was reconstituted as
recommended by the manufacturer and as described by Mutapi et
al. [25]. ELISAs were conducted as previously reported [22], using
5 mg/ml of SWAP antigen in carbonate bicarbonate buffer to coat
all ELISA plates, and adding sample at a 1:100 dilution in 5%
skimmed milk. Secondary IgG HRP-conjugated antibody was
added at a 1:1000 dilution for total IgG and IgG1, and at a 1:500
dilution for IgG2, IgG3 and IgG4. The colorimetric reaction was
left for 10 minutes for total IgG, and 15 minutes for the IgG
subclasses, and quantified with an ELISA reader at 405 nm. Each
antibody ELISA was performed in duplicate on the same day for
all samples with positive and negative controls on each plate.
Phenotyping of monocytes
Cryopreserved PBMCs were thawed as previously described
[33], and resuspended at 56106 cells/ml in PBS. Cells were
incubated with 10% FCS at 4uC for 10 minutes prior to staining
for 30 minutes with Alexa488 conjugated anti-CD14 (clone
M5E2), PE-Cy7 conjugated HLA-DR (clone L243) (both from
BD Biosciences, San Jose, CA), and Pacific Blue conjugated anti-
CD16 (clone CB16) (eBiosciences, San Diego, CA). Unbound
antibodies were washed off and cells were resuspended in PBS
prior to acquisition of at least 50,000 live events on a BD FACS
LSR II (BD Biosciences, San Jose, CA). Compensation was
performed prior to acquisition of each experiment using BD
FacsComp beads (BD Biosciences, San Jose, CA). Analysis was
performed using FlowJo software (TreeStar, USA) and mean
fluorescence intensity (MFI) was calculated for CD16.
To ensure that only CD14 positive cells representing monocytes
were analysed, only cells expressing both HLA-DR and CD14
were selected for analysis, in a gating strategy previously described
[28,34]. Briefly, a live gate to include all leukocytes was drawn
based on forward scatter (FSC) and side scatter (SSC), HLA-DR
positive cells were gated to exclude any CD16+ expressing natural
killer (NK) cells as well as other non-MHC expressing cells.
Monocytes were defined as CD14 or CD16 expressing cells. The
expression level of CD14 and CD16 was reported as MFI.
Statistical analysis
All statistical analyses were conducted using the statistical
package SPSS version 19 (IBM Corp, NY, USA). Due to the
possibility of gender and age dependent exposure patterns in this
population [35,36], appropriate statistical techniques were neces-
sary to adjust for this variation prior to investigating the
relationship of interest [37]. Parametric statistical modelling in
the form of analysis of variance (ANOVA) and linear regression
was therefore used. Data were transformed in order to meet
assumptions of parametric tests. Surface marker expression
(measured as MFI) was log transformed (log10(x+1)). Antibody
level (after subtraction of the blank control) was square root
transformed. Categorical variables were sex (male/female), infec-
tion status (uninfected/infected) and age group (5–10 years [age
group where infection is rising], 11–15 years [age group where
infection is peaking] or .16 years [age group where infection is
declining]).
To determine the extent of changes in the proportion of
monocytes relative to the rest of the PBMCs, ANOVA with
sequential sums of squares (SS) was used with the total number of
live monocytes as the dependent variable, and the independent
variables were sex (male or female), age group (5–10 years, 11–15
years or .16 years) and infection status (uninfected or infected).
Monocytes from different individuals show varying levels of
CD14 and CD16 expression intensity dependent on various
factors including age [38,39] and presence of inflammation [40].
Therefore, to test the hypothesis that CD14 and CD16 receptor
expression levels changed with infection and age group, a
multivariate analysis of variance (MANOVA) with sequential SS
was used with receptor expression (CD14 and CD16) as the
dependent variable, and the independent variables were sex, age
group and infection status. The model was extended to include an
interaction term between age and infection to assess patterns of
surface receptor expression co-dependent on age and infection
Table 1. Characteristics of study cohort.
Age Group
5–10 years 11–15 years .16 years
Infection Status Sh2 Sh+ Sh2 Sh+ Sh2 Sh+
Sample size (no.) 28 16 18 13 16 9
Mean Age (years) 7.68 7.62 13.17 12.54 30.12 27.11
Infection intensity 0 56.78 0 99.44 0 59.26
Infection range (SD) 0 1.33–297 (83.7) 0 0.33–523 (165.7) 0 0.33–550 (109.5)
Males:Females 8:20 11:5 9:9 8:5 2:14 3:6
All selected people of the cohort were negative for HIV, soil transmitted helminths and S. mansoni; infection intensity: eggs/10 mL urine; Sh2 negative for S.
haematobium, Sh+ positive for S. haematobium.
doi:10.1371/journal.pntd.0003049.t001
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status. The relationship between CD16 expression and age group
dependent on infection status was investigated further using a
partial correlation, controlling for variation due to sex, and
followed with Fisher’s z transformation, which tests for a
significance in the difference between two correlations.
The relationship between each of the anti-SWAP antibody titres
(total IgG, IgG1, IgG2, IgG3, IgG4) with infection and age group
was tested using a univariate ANOVA with sequential SS, entering
sex and age group before infection in the analysis. In addition, the
interaction between infection and age was tested and all
appropriate post-hoc tests were conducted.
Finally to determine the relationship between CD16 expression
on monocytes and antibody levels according to infection status, a
linear regression analysis was used. The relationship between
antibody levels and CD16 expression according to infection status
was investigated after accounting for sex and age differences, and
significant interactions were followed up with a correlation analysis
of the relationship between the two variables in uninfected and
infected individuals separately.
For all statistical tests significance of p#0.05 was considered
significant.
Results
The proportion of total circulating monocytes in
schistosome patients is similar to that in healthy
participants
The proportion of monocytes in PBMCs did not vary
significantly with host age or infection as shown in Figure 1A.
Thus, any changes observed in subsequent analyses will be a result
of changes in monocyte phenotype between individuals, rather
than as a result of changes in monocyte proportions, for example
due to migration of monocytes into or out of the vasculature.
Healthy older individuals express significantly higher
monocyte surface CD16 than schistosome infected
patients of the same age
The expression levels of CD14 and CD16 on monocytes were
investigated with relation to infection status. CD16 expression
levels were shown to vary dependent on age and infection status
(Table 2 and Figure 1B). Thus, while expression of CD16 on
monocytes was similar between infected (schistosome patients) and
uninfected (healthy) individuals in the younger age groups, with
increasing age there was an increasing intensity of expression in
the healthy individuals compared to a decreasing intensity of
expression with age in the infected individuals as shown in
Figure 1B. Consistent with the heterogeneous relationship
between age and infection status, the correlation coefficient was
significantly different (z = 2.97, p= 0.003) with schistosome
patients having a positive relationship (r = 0.350, p = 0.006) and
healthy individuals having a negative relationship (r =20.287,
p = 0.085). The oldest age group demonstrated significant
differences in monocyte CD16 expression dependent on infection
status (Figure 1B). In contrast, levels of the monocyte marker
CD14 did not vary with any of the investigated variables (Table 2
and Figure 1C).
Parasite-specific IgG levels increase with age in healthy
people, but not in schistosome patients
The relationship between SWAP-specific total IgG, as well as
the IgG subclasses and infection status dependent on age was
investigated. Total IgG, IgG1, IgG2 and IgG4, but not IgG3,
significantly varied with host age, with total schistosome-specific
IgG levels lowest in the age of peak schistosome infection, but the
adult worm-specific subclasses IgG1, IgG2 and IgG4 highest in the
oldest age group (Table 3). Overall, levels of parasite-specific IgG
and IgG1 varied between healthy participants compared to
schistosome infected people, with infected individuals having
greater antibody levels compared to uninfected individuals
(Table 3). However, only for total IgG, the effects of infection
status varied with host age as indicated by the significant age
group-infection status interaction term (Table 3). Figure 2 dem-
onstrates the gradual increase in levels of schistosome-specific total
IgG in healthy participants, while in schistosome infected patients,
total IgG levels did not change significantly with age. For total
IgG, IgG1, IgG3 and IgG4, but not IgG2, the youngest age group
showed significant differences in antibody levels dependent on
infection, with the infected individuals showing greater antibody
levels compared to the uninfected individuals (Figure 2).
CD16 expression level is related to parasite-specific IgG
and IgG1 levels in healthy participants but not in
schistosome patients
The relationship between intensity of CD16 expression on all
monocytes and IgG levels against SWAP was investigated to test
the hypothesis that innate cell (monocyte) phenotype is related to
schistosome-specific acquired immune markers (IgG). As both
CD16 expression and IgG antibody titres showed significant
relationships with infection status, the population was partitioned
by infection status prior to analysing the relationship between IgG
and CD16 by regression analysis. This analysis showed that in
healthy, uninfected individuals, expression levels of CD16 rose
significantly with levels of total IgG and IgG1 after allowing for
variation due to age and sex (Table 4). Expression levels of CD16
Figure 1. CD16 but not CD14 expression intensity on circulating monocytes differs between uninfected and infected older patients.
Proportion of (A) total circulating monocytes, (B) MFI of CD16, and (C) MFI of CD14 on monocytes according to age group and infection status and as
determined by flow cytometry. Open bars and open circles with dashed lines, healthy individuals; filled bars and closed circles with solid lines,
schistosome infected patients. Bars represent standard error of mean. Significant differences between infected and uninfected participants within age
groups according to sub-group analysis are indicated by *(p#0.05).
doi:10.1371/journal.pntd.0003049.g001
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in infected individuals did not show a relationship with parasite-
specific total IgG or IgG1. In addition, levels of IgG2, IgG3 and
IgG4 did not show a relationship with CD16 expression levels in
either infected or uninfected participants (Table 4).
Discussion
Human schistosome-specific IgE and IgG1 responses have been
shown to be associated with resistance to infection [41–43]. In
order to understand naturally developed protective immune
responses that can be targets for artificial induction through
vaccination, previous studies in schistosomiasis have focussed on
describing the interaction between IgE and cellular mediators of
protective effector responses, such as eosinophils and macrophages.
However, following Phase 1b vaccination trials on the human
hookworm vaccine candidate, it was found that inducing an IgE
response in naturally exposed people caused a pathological immune
response, compromising the vaccine’s safety [23]. Subsequently,
there has been a shift from developing IgE-mediated helminth
vaccines towards vaccines that induce the IgG1 and IgG3
subclasses. This study focused on determining the relationship
between schistosome-specific IgG subclasses and IgG FccRIIIa
(CD16) on humanmonocytes, a cell type related developmentally to
the macrophage and which has been shown to have a significant
role in immune responses to experimental schistosome infection.
Monocytes have previously been demonstrated to be involved in
immune response to schistosome larvae [11,12,44], and as
circulating cells interacting with adult schistosome stages in the
venules, monocytes are a highly relevant, but under studied innate
immune cell type in human schistosomiasis.
The relationship of increasing IgG subtypes with age, as well as
the higher expression of IgG against adult worm antigen in
infection, has previously been reported [20,45]. Anti-SWAP IgG1
and IgG4 are both dominant antibody subclasses in human
schistosomiasis, while IgG2 and IgG3 are detected at lower levels
[46]. In particular, IgG1 is associated with protection or
developing immunity [43] and IgG4 is associated with infection
[47]. These schistosome specific responses observed here in both
the older uninfected and infected groups confirm that both age
groups have been exposed to schistosome infection. Although the
age at which this exposure occurred in the uninfected group is not
clear, the increasing levels of all the antibody subclasses with age
represent the cumulative exposure to adult schistosome antigens
throughout the population’s lifetime. In human immuno-epide-
miological studies, the uninfected, older individuals are classified
as putatively resistant to infection via an immune-mediated
mechanism [43,48], and the gradual increase in parasite-specific
total IgG and IgG1 in this group is consistent with schistosome-
specific immune responses associated with protection [20,22].
The presence of infection in the older individuals who are
lifelong residents of this schistosome endemic area suggests that
they are carrying chronic infections, a fact that has been
corroborated by other studies conducted in the same area and
including some of the same participants [49]. In particular,
chitinase 3-like 1 protein, a marker of inflammation that has been
linked to schistosome-related hepatic fibrosis [50], was found to be
highest in the older people harbouring infection [49]. Indeed, with
increasing age, and thus duration of exposure to schistosomes,
differences in the immune system become more apparent, and
studies investigating myeloid derived dendritic cells from members
Table 2. Relationship between the MFI of CD14 or CD16 expression on monocytes with infection status and age group.
Monocyte marker
Independent variable CD16 CD14
Sex 5.370 (M,F) 0.235 (M.F)
Age group 0.813 (1,2,3) 0.157 (1.2,3)
Infection status 0.60 (sh2.sh+) 0.80 (sh2,sh+)
Infection status * Age group 4.946 0.772
F values of output of MANOVA for relationship between CD14 or CD16 and each factor. Model accounts for variation in sex (male (M) or female (F)), age group (1: 5–10
years; 2: 11–15 years; 3: .16 years), and infection status (uninfected: sh2; infected: sh+). The interaction term is designated by *. Direction of differences between
variables is indicated in brackets below F value. Significant values (p#0.05) are indicated in bold. N = 100.
doi:10.1371/journal.pntd.0003049.t002
Table 3. Variables affecting adult worm specific IgG levels.
Dependent variable
Independent variable Total IgG IgG1 IgG2 IgG3 IgG4
Sex 2.695 (M.F) 0.687 (M.F) 0.377 (M,F) 0.006 (M,F) 1.063 (M.F)
Age group 4.382 (1.2,3) 8.068 (1,2,3) 3.632 (1,2,3) 2.699 (1,2,3) 8.772 (1,2,3)
Infection status 9.040 (sh2,sh+) 5.302 (sh2,sh+) 0.782 (sh2,sh+) 1.520 (sh2,sh+) 2.152 (sh2,sh+)
Age group* Infection status 3.525 2.718 0.256 2.200 0.564
F values from ANOVA for relationship between antibody and variables. Model accounts for variation in sex (male (M) or female (F)), age group (1:5–10 years; 2: 11–15
years; 3:.16 years), and infection status (uninfected: sh2; infected: sh+). The interaction term is designated by *. Direction of differences between variables is indicated
in brackets below F value. Significant F values (p#0.05) are indicated in bold.
doi:10.1371/journal.pntd.0003049.t003
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of the same residential area have, similar to results presented here,
shown age related changes with infection [33]. In this study,
members of the younger patient cohort will have had a shorter
infection history compared to the older age groups, and therefore
have experienced much less schistosomiasis associated pathology
[5,42,51]. The differences in CD16 expression dependent on age
and infection may therefore be indicating an altered immune
activation status in relation to schistosome infection, and may
indicate a potential link between CD16 expression and pathology.
Indeed, the pattern of increasing CD16 expression with age,
observed here in the healthy individuals, has previously been noted
in other populations [38,39], and CD16 expression has previously
been reported to be upregulated with monocyte maturation and
activation [15,52].
The absence of a relationship between monocyte CD14
expression levels and schistosome infection is likely related to
CD14 being a lipopolysaccharide (LPS) receptor, which is involved
in immunity against bacterial challenge [53,54], and therefore
playing a less significant role in schistosome-specific responses
induced by adult worm antigens.
In contrast to the significant relationship between CD16 and
infection status shown here, we found no relationship between
infection intensity and either CD14 or CD16 expression (data not
shown), indicating that it was the presence of infection in the host
that was important in this relationship rather than the burden of
infection, a pattern that has been demonstrated in other
immunological and pathological features of human schistosomiasis
[49,55].
Table 4. Relationship between SWAP specific IgG and CD16 expression according to infection status.
CD16 MFI
Uninfected Infected
Antibody subclass b (SE) p-value b (SE) p-value
Total IgG 0.346 (0.268) 0.007 20.188 (0.280) 0.280
IgG1 0.282 (0.127) 0.032 20.069 (0.157) 0.704
IgG2 20.001 (0.148) 0.993 0.231 (0.129) 0.196
IgG3 0.083 (0.661) 0.538 0.053 (0.610) 0.771
IgG4 0.101 (0.095) 0.448 20.149 (0.091) 0.408
Regression (b) coefficients and the standard error (SE) and p-values from linear regression after accounting for sex and age differences. Significant p values and their
associated b coefficients are indicated in bold.
doi:10.1371/journal.pntd.0003049.t004
Figure 2. Total adult worm-specific IgG levels differ by age group in healthy participants but not schistosome patients. Adult worm
specific (A) total IgG, (B) IgG1, (C) IgG2, (D) IgG3, (E) IgG4 responses by age group and infection status measured by ELISA. Open circles and dashed
lines, healthy individuals; closed circles and solid lines, schistosome patients. Bars represent standard error of mean. Significant differences between
schistosome infected and uninfected participants within age groups according to sub-group analysis are indicated by p: ** p#0.005, *p#0.05.
doi:10.1371/journal.pntd.0003049.g002
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The positive correlation observed between the protective IgG
antibodies (total IgG and IgG1) and monocyte CD16 in uninfected
individuals, indicates that the CD16 expression level on monocytes
may be associated with protection against infection, in association
with an activated monocyte phenotype. Observations from
research into monocyte involvement in human HIV infection
report on CD16 - IgG mediated ADCC activity [56,57], and there
may be a similar mechanism mediating protection in schistosomi-
asis, in particular involving CD16-IgG1 interactions. However, the
precise role of any ADCC mechanism warrants further investiga-
tion. Importantly, consistent with results from mechanistic mouse
experimental studies of schistosomiasis [19], this relationship
suggests a link between the innate and adaptive arms of the
immune system in the response to schistosomiasis, which may be
important for furthering vaccine research efforts.
The lack of association between the other IgG subclasses, IgG2,
IgG3, and IgG4 may be due to antibody properties such as length
of memory response [58,59] and lack of affinity between the Fcc
receptor and the antibody, as is the case with IgG4; or the
relatively low levels of expression associated with schistosome
infection, as is the case with IgG3; or a combination of these
factors, as may be the case for IgG2.
Although the study cannot determine causality from the
observations made here, transfection studies of a macrophage cell
line demonstrated that chronic inflammation inhibits FcyRIIIa
(CD16) glycosylation, in turn reducing the ability for CD16
receptor activation following IgG binding [60]. Thus, chronically
infected individuals in this study may have deficiencies in their
CD16 receptor contributing to continued infection. In addition to
the Fcc receptor, CD16, monocytes also express CD32 (also
known as FccRIIb) an inhibitory receptor [61], and CD64 (also
known as FccR1a), a high affinity receptor for IgG [62].
Differential expression of these receptors may further indicate
the capability of monocytes to activate in response to infection,
and may enlighten on the role of other IgG subtypes in
schistosome infection.
Altogether, our study demonstrated that monocyte CD16
expression is associated with protection against schistosome
infection. The level of CD16 in healthy individuals is positively
associated with levels of total IgG and IgG1, antibodies which
have previously been associated with resistance to infection.
Conversely, in schistosome infected patients who are lifelong
residents of a schistosome endemic area, CD16 expression is
significantly reduced. This decrease in expression of a monocyte
activation marker, combined with the lack of association with
protective IgG, may be a result of an altered immune activation
state in chronic schistosomiasis infection.
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